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Diabetic kidney disease develops in half of genetically predisposed patients with type 2 diabetes (T2DM). Early diagnosis of kidney
damage and nephroprotective treatment are the ways of preventing the disease progression. Our aim was to evaluate selected
laboratory markers of glomerular and tubular damage in T2DM patients with early stages of chronic kidney disease (G1/G2,
A1/A2) for their associations with A2 albuminuria and early decline in the estimated glomerular filtration rate (eGFR). Among
80 T2DM patients with median eGFR of 92.4ml/min/1.73m2 and median urinary albumin to creatinine ratio (uACR) of
4.69mg/g, 19 had uACR> 30mg/g (A2). Higher serum cystatin C, serum and urine neutrophil gelatinase associated lipocalin
(NGAL), urine kidney injury molecule 1 (KIM-1), detectable urine transferrin and IgG, and lower serum uromodulin
significantly predicted A2 albuminuria, urine KIM-1/creatinine ratio, and IgG being the best predictors. Albuminuria, urine
NGAL/creatinine, and IgG correlated with diabetes duration. Albuminuria, urine NGAL, transferrin, IgG, and uromodulin
correlated with diabetes control. In a subgroup of 29 patients, retrospective data were available on changes in eGFR and uACR
over one year. Decline in eGFR was observed in 17 patients and increase in uACR in 10 patients. Serum and urine NGAL
correlated with eGFR changes. Higher urine NGAL, KIM-1/creatinine ratio, and detectable IgG were significantly associated
with the increase in uACR. Widely available markers, serum cystatin C, urine IgG, transferrin, and NGAL, may help in early
assessment of kidney disease in T2DM patients; however, large prospective studies are needed to confirm the conclusion.
1. Introduction
Diabetes is the most prevalent metabolic disease worldwide,
and its complications are among the most important public
health issues [1]. About 30–40% of diabetic patients, espe-
cially the genetically predisposed ones, develop diabetic
kidney disease (DKD), which makes it the most frequent
cause of end-stage kidney disease and renal replacement
therapy [2, 3].
Early diagnosis and early initiation of nephroprotective
therapy have the potential to prevent the progression of
DKD toward end-stage renal disease and to improve patients’
prognosis. Based on the guidelines issued by Kidney Disease
Outcomes Quality Initiative (KDOQI) in 2007 [4], the
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repeated assessment of urine albumin/creatinine ratio
(uACR) in two to three samples of morning urine together
with the estimation of glomerular filtration rate (eGFR) has
been recognized as the best standard screening for DKD.
However, currently, it is well known that kidney damage in
course of type 2 diabetes mellitus (T2DM)may occur without
increased albuminuria [5]. Moreover, decrease in eGFR is not
an early indicator of diabetic renal damage. Therefore, in
some patients, albuminuria and eGFR are not sensitive
markers of early DKD. Diagnostic imaging produces nonspe-
cific results in DKD patients, and the thick needle biopsy is
very rarely used due to invasiveness and the lack of strict
clinical indications in the early stage of DKD, usually
characterized by very few symptoms. Thus, there is a need
to seek new biomarkers of early renal damage in patients
with T2DM.
Morphological changes observed in kidneys in the
course of DKD affect almost all nephron structures:
glycocalyx and glomerular endothelial cells, glomerular
basement membrane, podocytes and slit membranes,
mesangial matrix, renal interstitium, and renal tubules [6].
To properly qualify the potential markers of renal damage
in T2DM, it is useful to classify them according to the renal
structure affected by the pathological process [7]. On this
basis, we distinguish markers of glomerular damage includ-
ing transferrin, immunoglobulin G (IgG), ceruloplasmin,
type IV collagen, laminin, glycosaminoglycans, lipocalin-
type prostaglandin D synthase, fibronectin, podocalyxin,
vascular endothelial growth factor, cystatin C (CysC), or
nephrin and markers of tubular damage such as neutrophil
gelatinase-associated lipocalin (NGAL), alpha-1-microglob-
ulin, kidney injury molecule-1 (KIM-1), N-acetyl-beta-D-
glucosaminidase, angiotensinogen, uromodulin, liver-type
fatty acid-binding protein (L-FABP), heart-type fatty acid-
binding protein (H-FABP), the products of advanced
glycation, or inflammatory markers [8]. Some biomarkers,
including albumin, are filtered in the glomeruli and then
reabsorbed in the proximal tubule of the nephron; increased
urine excretion of such markers may indicate damage of both
glomerular and tubular structures [7].
The aim of the study was the assessment of selected
laboratory markers of glomerular and tubular damage in
serum and urine of T2DM patients without significant
decrease in the glomerular filtration rate and without signif-
icantly increased albuminuria. We evaluated the studied
biomarkers as the predictors of moderately increased
albuminuria and evaluated their associations with early
decline of kidney function in T2DM.
2. Materials and Methods
2.1. Study Group. The cross-sectional study recruited consec-
utive patients with T2DM consulted at the ambulatory clinic
of Nephrology Department of Clinical District Hospital
No. 2 in Rzeszów, Poland, between October 2014 and
November 2015. The study visit was a part of a standard care
and was either arranged to assess kidney function in newly
diagnosed T2DM patients or was a control visit of patients
with single benign renal cysts or following treatment of
urinary tract infection. A subgroup of patients attended a
control visit as a part of longitudinal observation of changes
in eGFR and urine albumin/creatinine ratio (uACR) [9].
Inclusion criteria were T2DM diagnosis, eGFR> 60ml/min/
1.73m2, and uACR< 300mg/g. We excluded patients
diagnosed with anemia, neoplasm, connective tissue disease,
infection, allergy, treated with potentially nephrotoxic
drugs, and with known renal disease other than DKD.
Moreover, patients with poorly controlled hypertension,
decompensated heart failure, urinary tract infection, after
increased physical activity, and women during menstrua-
tion as well as pregnant women were excluded to avoid
nonspecific albuminuria.
Patients were subjected to detailed medical examination.
Patient’s history was collected focusing on the presence of
comorbidities, their duration, and treatment. Weight, height,
and blood pressure were measured; body mass index (BMI)
was calculated, and laboratory tests were ordered. According
to 2012 KDOQI guidelines [10], kidney impairment was
assessed based on uACR and eGFR estimated using 2009
Chronic Kidney Disease Epidemiology Collaboration for-
mula based on serum creatinine (CKD-EPICr). Moderately
increased albuminuria (uACR between 30 and 300mg/g or
A2 albuminuria category) was considered the objective
evidence of kidney disease, according to the definition of
chronic kidney disease issued by Kidney Disease: Improving
Global Outcomes (KDIGO) [11].
In a subgroup of patients, retrospective data were
available on eGFR values and uACR changes over one-year
observation. These patients were seen a year and 6 months
before the study visit. During the previous visits, patients
were instructed to maintain physical activity and diabetic
diet. The doses of insulin or oral hypoglycemic drugs
were adjusted to maintain good glycemic control. Renin-
angiotensin-aldosterone system inhibitors were used as
antihypertensive drugs, and statins were used in treatment
of dyslipidemia if not contraindicated [12]. We assumed
the decrease in eGFR based on serum creatinine and
the increase in urine albumin/creatinine ratio after one
year of observation as the indicators of kidney function
decline [13, 14].
All patients provided informed consent for the study. The
study protocol was approved by the Bioethics Committee of
the Regional Medical Chamber in Rzeszów, Poland (approval
number 70/2017/B issued on 19th September 2014).
2.2. Laboratory Tests. First morning urine and fasting blood
sample were collected for laboratory measurements at the
day of the study visit. The laboratory tests included routine
tests used for the assessment of the patients’ health status,
and a set of additional tests was performed for the purpose
of this study.
The routine tests included fasting serum glucose, glycated
hemoglobin A1c (HbA1c), complete blood count, lipid profile,
serum C-reactive protein (CRP), and creatinine. GFR was
estimated based on serum creatinine according to CKD-
EPICr formula [8]. Urinalysis with urine sediment analysis
was performed using the first morning urine sample to
exclude urinary tract infection. First morning urine samples
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were also tested for the concentration of NGAL, albumin,
and creatinine, and then, uACR and urine NGAL/creatinine
ratios (uNGAL/Cr) were calculated. The measurements of
uNGAL were conducted using chemiluminescent micropar-
ticle immunoassay and Architect analyzer (Abbott Diagnos-
tics, Lake Forest, IL, USA). Urine albumin concentrations
were measured using an immunoturbidimetric method, and
creatinine concentration was assessed using an enzymatic
method on Olympus/Beckman Coulter Chemistry Analyzer
AU680 (Beckman Coulter, Brea, USA). Peripheral blood
counts were performed using a hematology analyzer ADVIA
2120i (Siemens Healthcare, Erlangen, Germany). Urinalysis
was performed using LabUMat-UriSed 2 analyzer. The
routine tests and uNGAL measurements were performed
on the day of samples’ collection in the Department of
Diagnostics of St. Queen Jadwiga Clinical District Hospital,
Rzeszów, Poland.
The remaining serum and urine were aliquoted and
frozen in −80°C until the complete set of samples was
collected. The tests were performed in series to avoid the
cycles of repeated freezing/defreezing. The preserved mate-
rial was used to determine the concentrations of transferrin,
IgG, KIM-1, and uromodulin (uUMOD) in urine and NGAL,
CysC, and uromodulin (sUMOD) in serum. Transferrin,
IgG, and CysC were measured using an immunonephelo-
metric method on a Nephelometer II analyzer (Siemens
Healthcare, Erlangen, Germany) at the Diagnostics Depart-
ment, University Hospital, Kraków, Poland. The upper
reference limits were, respectively, 2.17mg/l for urine trans-
ferrin and 3.36mg/l for urine IgG. The reference range for
serum cystatin C was 0.59–1.04mg/l. The concentrations of
sUMOD, uUMOD, serum NGAL, and urine KIM-1 were
determined using commercially available enzyme-linked
immunosorbent assays with a Human Uromodulin ELISA
kit (BioVendor, Brno, Czech Republic), a Human Lipoca-
lin-2/NGAL ELISA kit (BioVendor, Brno, Czech Republic),
and Quantikine ELISA Human TIM-1/KIM-1/HAVCR
Immunoassay (R&D Systems, McKinley Place, MN, USA),
respectively. The readings were done with an automatic
microplate reader Automatic Micro ELISA Reader ELX 808
(BioTek Instruments Inc., Winooski, VT, USA). The refer-
ence range for sUMOD determined by the manufacturer of
the kit was 37.0–501.0 ng/ml (mean 241 ng/ml); the limit
of detection was 0.12 ng/ml. The reference range for urine
KIM-1 values determined by the manufacturer of the kit
was 0.156–5.33 ng/ml, and mean detectable concentration
was 0.009 ng/ml. The limit of detection of NGAL in
serum was 0.02ng/ml, and the reference values were
63.5± 33.4 for men and 64.9± 46.5 ng/ml for women.
Uromodulin, serum NGAL, and KIM-1 measurements were
performed in the Department of Diagnostics, Chair of
Clinical Biochemistry, Jagiellonian University Medical
College, Kraków, Poland.
2.3. Statistical Analysis. Data were presented as number of
patients (percentage of the group) for categories, mean±
standard deviation or median (lower-upper quartile)
for quantitative variables with normal and nonnormal
distributions (as checked using Shapiro-Wilk’s test).
Spearman’s rank correlation coefficient was used to
study correlations. Differences between groups were tested
with t-test and Mann–Whitney’s test, according to distri-
butions. Simple and multiple logistic regressions were used
to assess predictors of G1/G2 A2 CKD. Odds ratios (OR)
with 95% confidence intervals (95% CI) were reported as
results of logistic regression. The variables that proved
significant predictors in simple logistic regression were
studied further using receiver operating characteristic
(ROC) curves’ analysis to assess the diagnostic accuracy.
Cut-off values were chosen by maximizing the Youden
index. The statistical tests were two-tailed, and the results
were considered significant at p < 0 05. Statistica 12.0
(StatSoft, Tulsa, USA) was used for computations.
3. Results
3.1. Characteristics of Patients. The study recruited 80
patients with T2DM with median eGFR (CKD-EPICr)
of 92.4ml/min/1.73m2 (79.7–101.0ml/min/1.73m2) and
median uACR of 4.69mg/g (2.86–19.17mg/g). The
patients presented with typical comorbidities, including
hypertension in (67) 84%, ischemic heart disease in 10
(12%), and heart failure in 6 (7%). In most patients, diabetes
was well controlled: median HbA1c concentrations equaled
6.4% (5.9–7.9%). The treatment of diabetes included metfor-
min in 74 patients (93%). Insulin therapy was necessary in
25 patients (31%).
Most patients (N = 61; 77%) had normal to mildly
increased albuminuria (uACR< 30mg/g). Moderately
increased albuminuria (uACR between 30 and 300mg/g)
was observed in 19 patients (23%) (Table 1). On average,
these patients were older and had longer known duration of
diabetes, as well as higher HbA1c (Table 1). Ischemic heart
disease was more commonly associated with moderately
increased albuminuria; however, no significant differences
regarding other comorbidities nor treatment modalities
were observed between patients with normal and moder-
ately increased albuminuria (Table 1). Moreover, white
blood cell counts and C-reactive protein concentrations
were higher among patients with uACR between 30 and
300mg/g (Table 1).
3.2. The Associations of Studied Markers with Moderately
Increased Albuminuria. Serum cystatin C, serum NGAL,
urine NGAL and NGAL/creatinine ratios, urine KIM-1
and KIM-1/creatinine ratio, urine transferrin, and urine
IgG were significantly higher among patients with moder-
ately increased albuminuria while serum uromodulin was
significantly lower in this group of patients (Table 1). High
serum cystatin C, serum NGAL, urine NGAL and NGAL/
creatinine ratio, urine KIM-1 and KIM-1/creatinine ratio,
detectable urine transferrin, and urine IgG as well as low
serum uromodulin were also significant predictors of
moderately increased albuminuria in simple logistic
regression (Table 2). Most of these predictors (except for
serum concentrations of cystatin C, NGAL, and uromodulin)
were independent of age, diabetes duration, the presence
of hypertension, heart failure, and the treatment with
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renin-angiotensin-aldosterone system inhibitors (Table 2).
In ROC curves’ analysis, urine KIM-1/creatinine and urine
IgG showed highest values of the area under the ROC
curve, being the best markers to discriminate between
patients with and without moderately increased albumin-
uria (Figure 1, Table 3). In case of most studied markers,
the cut-off values selected to best discriminate between
patients with normal to mildly increased and moderately
increased albuminuria fell within the values observed in
healthy individuals. However, this was not the case for
serum cystatin C, urine transferrin, and urine IgG, where
the selected cut-off values were slightly higher than the upper
reference limit established by our laboratory. Among 61
patients with uACR< 30mg/g, 11 patients (18%) had serum
cystatin C above the upper reference limit of 1.04mg/l,
4 (7%) had urine IgG above the upper reference limit of
3.36mg/l, and 1 (2%) had urine transferrin above the
upper reference limit of 2.17mg/l.
Table 1: Clinical characteristics and the results of laboratory tests of T2DM patients with eGFR> 60ml/min/1.73m2 according to
albuminuria categories.
Characteristic
Normal to mildly increased albuminuria:
uACR< 30mg/g (N = 61)
Moderately increased albuminuria:
uACR 30–300mg/g (N = 19) p value
Age, years 59± 11 67± 12 0.007#
Male sex, N (%) 32 (52) 6 (32) 0.1
Known diabetes duration, years 5 (2–10) 10 (6–15) 0.009#
Hypertension, N (%) 50 (82) 17 (89) 0.4
Ischemic heart disease, N (%) 5 (8) 5 (26) 0.037#
Heart failure, N (%) 3 (5) 3 (16) 0.1
BMI, kg/m2 31.5± 5.0 31.9± 7.5 0.8
Insulin treatment, N (%) 17 (28) 8 (42) 0.2
Statin use, N (%) 27 (44) 13 (68) 0.07
ACEI/ARB use, N (%) 40 (66) 13 (68) 0.8
Hemoglobin, g/dl 14.0± 1.4 13.2± 1.7 0.045#
White blood cell count, ×103/μl 7.20 (6.20–8.33) 8.51 (6.65–10.30) 0.039#
Fasting glucose, mmol/l 6.95± 0.84 7.25± 0.70 0.2
HbA1c, % 6.30 (5.90–7.80) 7.35 (6.30–8.40) 0.049
#
Total cholesterol, mmol/l 4.68 (3.85–5.74) 4.84 (3.98–5.72) 0.8
HDL-cholesterol, mmol/l 1.19 (1.06–1.42) 1.22 (1.01–1.40) 0.7
LDL-cholesterol, mmol/l 2.66 (1.86–3.49) 2.49 (1.94–3.54) 0.8
Triglycerides, mmol/l 1.53 (1.15–2.03) 1.83 (1.40–2.80) 0.07
C-reactive protein, mg/l 2.80 (1.30–5.80) 6.90 (3.40–14.60) 0.008#
Serum creatinine, μmol/l 68.1 (59.2–78.7) 64.5 (53.0–79.6) 0.6
eGFR (CKD-EPICr), ml/min/1.73m
2 94 (81–101) 86 (72–97) 0.2
Serum cystatin C, mg/l 0.86 (0.78–1.01) 1.15 (0.93–1.37) <0.001#
eGFR (CKD-EPICysC), ml/min/1.73m
2 93 (78–103) 71 (62–95) 0.002#
Serum NGAL, μg/l 53.8 (43.3–70.4) 67.2 (61.0–103.1) 0.013#
Urine NGAL, μg/l 10.3 (3.1–21.8) 24.7 (14.3–43.9) 0.008#
Urine NGAL/creatinine, μg/g 9.02 (2.97–18.84) 35.1 (8.89–74.92) 0.012#
Urine KIM-1, μg/l 0.73 (0.32–1.54) 1.26 (0.73–2.92) 0.022#
Urine KIM-1/creatinine, μg/g 0.98 (0.30–1.31) 1.91 (1.20–3.29) <0.001#
Urine transferrin, mg/l <2.17 <2.17 (<2.17–6.43) <0.001#
Detectable urine transferrin (≥2.17mg/l), N (%) 1 (2) 9 (47) <0.001#
Urine IgG, mg/l <3.36 5.88 (<3.36–12.60) <0.001#
Detectable urine IgG (≥3.36mg/l), N (%) 4 (7) 14 (74) <0.001#
Serum uromodulin, μg/l 127 (95–173) 100 (58–138) 0.031#
Urine uromodulin, mg/l 6.56 (2.19–14.38) 5.60 (2.09–13.41) 0.5
Urine uromodulin/creatinine, mg/g 7.62 (2.18–15.95) 9.19 (3.31–12.79) 0.8
#Statistically significant difference between the groups. Abbreviations: T2DM: type 2 diabetes mellitus; uACR: urine albumin to creatinine ratio; BMI: bodymass
index; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; HbA1c: glycated hemoglobin A1c; HDL: high-density lipoprotein;
LDL: low-density lipoprotein; eGFR: estimated glomerular filtration rate; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; Cr: creatinine; CysC:
cystatin C; NGAL: neutrophil gelatinase-associated lipocalin; KIM-1: kidney injury molecule-1; IgG: immunoglobulin G.
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3.3. Correlations of Studied Markers with eGFR,
Albuminuria, Diabetes Duration, and Diabetes Control.
Except for serum cystatin C, the studied serum and urine
markers of renal function did not significantly correlate with
eGFR based on serum creatinine (Table 4). Patients with
detectable IgG and those with detectable transferrin had on
average lower eGFR values (median 86 and 83ml/min/
1.73m2, resp.) than those with undetectable concentrations
(median 93ml/min/1.73m2 for both patients with undetect-
able IgG and those with undetectable transferrin); however,
the differences were not statistically significant (p = 0 2 in
case of transferrin, p = 0 3 in case of IgG).
Urine albumin, albumin/creatinine ratio, NGAL/creati-
nine ratio, and IgG significantly correlated with known
duration of diabetes (Table 4). However, only serum cystatin
C (R = 0 61; p < 0,001) and serum uromodulin (R = −0 26;
p = 0 018) were significantly correlated with age. Moreover,
urine albumin, uACR, urine NGAL and NGAL/creatinine
ratio, urine transferrin, urine IgG, urine uromodulin, and
uromodulin/creatinine ratio significantly correlated with
diabetes control as reflected by HbA1c concentrations. Urine
markers NGAL, KIM-1, IgG, and transferrin were corre-
lated with albuminuria (Table 4). Except for serum NGAL
(R = 0 45; p < 0 001), the studied markers were not corre-
lated with C-reactive protein. Also, none correlated with
BMI. None of the studied markers differed significantly
between men and women, between patients with and
without hypertension, or between those treated and not
treated with renin-angiotensin-aldosterone inhibitors.
3.4. Associations between Concentrations of Studied Markers
and Follow-Up Data. Among 29 patients (36% of the study
group), the retrospective data were available that had been
recorded one year before the study visit. The retrospective
data included eGFR and uACR values. During the year,
GFR decreased in 17 patients (59%) (Table 5). Median
decrease equaled 5.2ml/min/1.73m2, that is, 7.6% of the
initial eGFR value. Among studied markers, only higher
NGAL concentrations both in serum and in urine were
significantly associated with decrease in eGFR (Table 5).
Moreover, the concentrations of serum NGAL, urine NGAL,
and urine NGAL/creatinine ratios correlated negatively with
the percentage changes in eGFR over the year (Figure 2).
During the one-year observation, uACR increased in
10 patients (34%), with median increase of 12.2mg/g. We
observed no relationship between the decrease in eGFR and
the increase in albuminuria (p = 0 9). However, higher urine
NGAL, urine NGAL/creatinine ratio, urine KIM-1/creatinine
ratio, and detectable urine IgG were significantly associated
with the increase in uACR (Figure 3).
We compared the longitudinal data (i.e., the incidence of
decrease in eGFR and increase in uACR over one-year obser-
vation) between patients with studied markers below and
above the cut-off values selected in a cross-sectional study
(as presented in Table 3). Serum NGAL above 61μg/l was
the only marker significantly associated with more prevalent
decrease in eGFR (it occurred in 53% of patients with serum
NGAL above the cut-off versus 17% of those with serum
NGAL below the cut-off; p = 0 047). However, several
markers were associated with more prevalent increase in
uACR, that is, urine NGAL above 14.3μg/l (70% versus
32%; p = 0 048), urine NGAL/creatinine above 28.3μg/g
(50% versus 11%; p = 0 023), urine KIM-1/creatinine above
1.81μg/g (50% versus 11%; p = 0 018), and urine IgG above
3.49mg/l (50% versus 5%; p = 0 005).
4. Discussion
Based on KDOQI definitions [4, 10], DKD diagnosis is
based on increased albuminuria and decreased eGFR.
However, there are several weaknesses of albuminuria as
a marker of (early) DKD. Most importantly, among
T2DM who develop kidney disease associated with
decrease in glomerular filtration, there are about 30–45%
Table 2: Odds ratios for moderately increased albuminuria (uACR between 30 and 300mg/g) among T2DM patients with eGFR> 60ml/
min/1.73m2 in simple and multiple logistic regressions adjusted for age, diabetes duration, the presence of hypertension, heart failure, and
the treatment with renin-angiotensin-aldosterone system inhibitors.
Predictor variable
Simple analysis Multiple analysis
Odds ratio (95% confidence interval) p value Odds ratio (95% confidence interval) p value
Serum creatinine, per 1μmol/l 0.99 (0.96–1.02) 0.6 0.98 (0.94–1.01) 0.2
Serum cystatin C, per 1mg/l 33.09 (2.82–387.83) 0.005# 14.98 (0.64–353.13) 0.09
Serum NGAL, per 1μg/l 1.02 (1.00-1.04) 0.018# 1.02 (1.00-1.04) 0.059
Urine NGAL, per 1μg/l 1.04 (1.01–1.07) 0.016# 1.04 (1.00-1.07) 0.035#
Urine NGAL/creatinine, per 1μg/g 1.02 (1.00-1.035) 0.018# 1.02 (1.00-1.04) 0.035#
Urine KIM-1, per 1μg/l 1.64 (1.09–2.45) 0.020# 1.87 (1.11–3.15) 0.016#
Urine KIM-1/creatinine, per 1 μg/g 5.63 (2.16–14.68) <0.001# 7.12 (2.22–22.87) <0.001#
Detectable urine transferrin 54.00 (5.95–490.37) <0.001# 54.90 (4.70–640.90) 0.001#
Detectable urine IgG 39.90 (9.25–172.10) <0.001# 59.37 (8.54–412.79) <0.001#
Serum uromodulin, per 1μg/l 0.99 (0.98–1.00) 0.049# 0.99 (0.98–1.00) 0.09
Urine uromodulin, per 1mg/l 0.96 (0.89–1.02) 0.2 0.95 (0.88–1.03) 0.2
Urine uromodulin/creatinine, per 1mg/g 1.00 (0.95–1.06) 0.9 1.01 (0.95–1.07) 0.8
#Statistically significant result. Abbreviations: see Table 1.
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in whom no increased albuminuria (of above 30mg/g
creatinine) is observed [15, 16]. Further, albuminuria is not
specific for DKD, and the comorbidities often observed in
T2DM (such as hypertension or obesity) may also affect
the filtration barrier of the glomeruli leading to increased
albuminuria [17]. Moreover, treatment of hypertension
often includes renin-angiotensin-aldosterone inhibitors
(angiotensin-converting enzyme inhibitors and angioten-
sin receptor blockers) that lower hydrostatic pressure in
glomeruli and thus normalize albuminuria. Although benefi-
cial, this effect influences the diagnosis of DKD based on
current guidelines [10]. There is an ongoing debate on lower-
ing the cut-off value for albuminuria; evidence exists that the
urine albumin/creatinine ratio exceeding 15mg/g should be
used to define chronic kidney disease as it better predicts
kidney disease-related cardiovascular complications [18].
On the other hand, decreased eGFR occurs rather late follow-
ing changes in the kidney in DKD, the early damage being
often accompanied by hyperfiltration [19]. Both routine
markers of DKD (albuminuria and eGFR) are altered in
consequence of the damage to renal glomeruli. However, in
about 30% of T2DM patients with kidney impairment,
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Figure 1: Receiver operating characteristic curves for selected serum and urine markers used to diagnose moderately increased albuminuria
(uACR between 30 and 300mg/g) among T2DM patients with eGFR> 60ml/min/1.73m2: (a) serum cystatin C (sCysC); (b) serum
uromodulin (sUMOD); (c) serum NGAL (sNGAL); (d) urine NGAL (uNGAL); (e) urine NGAL/creatinine (uNGAL/Cr); (f) urine
transferrin (uTRF); (g) urine KIM-1 (uKIM-1); (h) urine KIM-1/creatinine (uKIM-1/Cr); (i) urine IgG (uIgG).
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changes in renal interstitium and tubules precede damage of
glomeruli [20]. Nevertheless, markers of tubular damage are
currently not a part of routine assessment of T2DM patients.
Our study is a part of extensive efforts aiming at the
evaluation of other urinary and serum markers for their
possible usefulness in early diagnosis of DKD. However, we
used eGFR and albuminuria as the standard indicators of
renal function at baseline and after one year of follow-up.
Our study recruited patients without significant decrease
in eGFR and without severely increased albuminuria.
According to currently accepted definitions [11], in individ-
uals with eGFR> 60ml/min/1.73m2, moderately increased
albuminuria serves as the evidence of stage A2 chronic
kidney disease. In our study, patients with A2 albuminuria
presented higher concentrations of most studied markers
of both glomerular (serum cystatin C, urine IgG, and
transferrin) and tubular damage (urine and serum NGAL,
urine KIM-1), as well as lower serum concentrations of
uromodulin. A2 patients were older, with longer history
of diabetes, and there was a positive correlation between
albuminuria and diabetes control, similar to previous
reports [21]. Still, in case of urine IgG, transferrin, NGAL,
and KIM-1, the difference between A1 and A2 subgroups
remained significant after adjustment for age, diabetes
duration, and comorbidities (hypertension and heart failure)
as well as treatment with renin-angiotensin-aldosterone
system inhibitors.
Using ROC curves analysis, we determined the cut-off
values that best discriminate between A1 and A2 patients.
The cut-off values for studied markers of glomerular
damage, that is, serum cystatin C, urine IgG, and transfer-
rin were higher as compared with upper reference limits
Table 3: Diagnostic accuracy data for selected serum and urine markers used to diagnose moderately increased albuminuria (uACR between
30 and 300mg/g) among T2DM patients with eGFR> 60ml/min/1.73m2. Values observed in healthy individuals are shown to enable
comparison with selected cut-off values.
Marker
Reference values previously
associated with healthy individuals
Detection of moderately increased albuminuria in T2DM
AUC (95% CI) Selected cut-off value Sensitivity, % Specificity, %
Serum cystatin C, mg/l 0.59–1.04a 0.78 (0.65–0.91) 1.09 68 90
Serum NGAL, μg/l
Men 63.5± 33.4
Women 64.9± 46.5b 0.69 (0.56–0.83) 61.0 79 61
Urine NGAL, μg/l 10.9 (6.0–38.2)c 0.74 (0.60–0.87) 14.3 80 61
Urine NGAL/creatinine, μg/g 12.2 (5.9–27.9)c 0.71 (0.53–0.89) 28.3 60 87
Urine KIM-1, μg/l 0.156–5.33b 0.68 (0.54–0.81) 0.73 79 51
Urine KIM-1/creatinine, μg/g 0.225–3.20b 0.84 (0.72–0.95) 1.81 67 92
Urine transferrin, mg/l <2.17a 0.73 (0.58–0.88) 2.41 47 98
Urine IgG, mg/l <3.36a 0.85 (0.72–0.97) 3.49 74 93
Serum uromodulin, μg/l∗ 191.2 (89.1–299.1)c 0.66 (0.53–0.80) 144 95 43
aReference interval used in the laboratory that performed the measurement for the present study. bReference values reported by the manufacturer of the test
used in the present study [43–45]. cPreviously reported values measured in the same laboratory and with the same tests as in the present study: urine
NGAL, urine NGAL/creatinine [46], and serum uromodulin [38]. ∗Low concentrations are associated with renal impairment. Abbreviations: see Table 1.
Table 4: Correlations between studied serum and urine markers and eGFR, diabetes duration, and HbA1c concentrations.
Marker
eGFR (CKD-EPICr) Diabetes duration HbA1c uACR
R p value R p value R p value R p value
Serum cystatin C −0.72 <0.001# 0.17 0.1 −0.05 0.7 0.21 0.08
Urine albumin 0.02 0.9 0.21 0.071 0.28 0.020# NA
Urine albumin/creatinine −0.01 0.9 0.25 0.037# 0.29 0.015# NA
Serum NGAL −0.15 0.2 0.09 0.4 0.10 0.4 0.13 0.3
Urine NGAL −0.06 0.6 0.19 0.1 0.24 0.048# 0.39 <0.001#
Urine NGAL/creatinine −0.05 0.7 0.24 0.046# 0.25 0.035# 0.36 0.002#
Urine KIM-1 0.11 0.4 −0.03 0.8 0.08 0.5 0.32 0.005#
Urine KIM-1/creatinine 0.05 0.7 0.05 0.7 0.16 0.2 0.45 <0.001#
Urine transferrin −0.17 0.1 0.19 0.1 0.32 0.006# 0.48 <0.001#
Urine IgG −0.14 0.2 0.27 0.016# 0.33 0.005# 0.61 <0.001#
Serum uromodulin 0.16 0.2 0.06 0.6 0.03 0.8 −0.09 0.4
Urine uromodulin 0.08 0.5 −0.14 0.2 −0.35 0.002# −0.03 0.8
Urine uromodulin/creatinine 0.04 0.7 −0.12 0.3 −0.32 0.009# 0.01 0.9
#Statistically significant correlation. Abbreviations: see Table 1; NA: not applicable.
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established in healthy individuals. A substantial proportion
(18%) of G1-G2/A1 patients presented with serum cystatin
C above the upper reference limit, in line with previous
reports [22, 23]. In our study, neither of the tubular
markers was significantly correlated with eGFR based on
serum creatinine. Moreover, serum creatinine and eGFR
based on creatinine did not differ between our A1 and
A2 patients, while serum cystatin C and eGFR based on
cystatin C differed significantly. The KDIGO guidelines
[11] recommend the estimation of GFR based on serum
cystatin C in adult patients with suspected stage G3a of
chronic kidney disease (GFR between 45 and 60ml/min/
1.73m2). Our results suggest that measurements of serum
cystatin C accompanied by calculation of eGFR with the
use of CKD-EPICycC equation may be useful already at the
earlier stages of diabetic kidney disease. The recently
performed laboratory standardization of cystatin C measure-
ments is also the advantage that must be remembered.
Urine IgG and transferrin excretion has been previously
observed in normoalbuminuric patients with diabetes and
has been associated with hypertension and hyperfiltration
[24, 25]. In accordance with previous studies [26, 27], we
observed increased urine IgG and transferrin in a subgroup
with moderately increased albuminuria and both proteins
were specific markers of kidney disease. These are notable
observations, especially considering high molecular weight
of IgG (150 kDa) that preserves the protein from being
filtered by healthy glomeruli [28].
In our study, both urine NGAL and KIM-1 correlated
positively with albuminuria, consistently with previous
reports regarding patients with T2DM [29–31] and were
significantly higher in patients with moderately increased
albuminuria. Nauta et al. [32] observed higher concentra-
tions of urine NGAL and KIM-1 in normoalbuminuric
diabetic patients comparing to healthy subjects. Also, we
have previously reported increased urine NGAL concentra-
tions among patients with early stages or risk for DKD
[33], similarly to other groups [34, 35].
Tamm-Horsfall’s protein or uromodulin is the main pro-
tein present in normal urine. This glycoprotein is exclusively
expressed in the thick ascending limb of the loop of Henle
and proximal part of the distal renal tubule and is released
to urine by partial proteolysis [36]. It was demonstrated that
the damage of renal tubules in chronic kidney disease
(including early stages: G1 and G2) was associated with
reduced concentrations of uromodulin in both urine and
serum [37–39], which reflects a pathophysiological difference
of this glycoprotein compared to other renal tubule injury
markers. In our study, neither serum nor urine concentra-
tions of uromodulin were correlated with albuminuria.
Moreover, we have not observed correlations between
uromodulin and eGFR. However, an interesting observation
Table 5: Characteristics of 29 patients for whom retrospective longitudinal data were available. The group was divided according to changes
in eGFR over one-year observation.
Characteristic
Patients with decrease
in eGFR (N = 17)
Patients without decrease
in eGFR (N = 12) p value
Age, years 64± 15 63± 11 0.4
Male sex, N (%) 11 (65) 6 (50) 0.4
Known diabetes duration, years 7 (2–11) 10 (4–11) 0.4
HbA1c, % 6.10 (5.70–6.45) 6.20 (5.70–7.00) 0.7
Serum creatinine, μmol/l 61.9 (59.2–72.5) 68.9 (61.4–77.8) 0.5
eGFR (CKD-EPICr), ml/min/1.73m
2 91 (81–98) 96 (80–99) 0.8
Serum cystatin C, mg/l 0.92 (0.82–1.14) 0.86 (0.76–1.10) 0.2
eGFR (CKD-EPICysC), ml/min/1.73m
2 87 (67–96) 96 (70–105) 0.2
Urine albumin, mg/l 8.06 (6.76–13.53) 10.18 (6.21–14.65) 0.9
Urine albumin/creatinine, mg/g 7.93 (3.38–13.38) 8.07 (5.50–16.4) 0.6
Serum NGAL, μg/l 66.7 (49.7–72.3) 44.4 (39.7–55.0) 0.028#
Urine NGAL, μg/l 15.3 (4.0–31.5) 2.9 (1.9–18.5) 0.048#
Urine NGAL/creatinine, μg/g 6.47 (3.36–45.78) 8.82 (2.42–20.3) 0.3
Urine KIM-1, μg/l 1.05 (0.42–1.64) 1.12 (0.35–1.69) 0.9
Urine KIM-1/creatinine, μg/g 1.01 (0.55–1.58) 1.34 (0.59–2.23) 0.5
Urine transferrin, mg/l <2.17 <2.17 0.1
Detectable urine transferrin (≥2.17mg/l), N (%) 0 2 (17) 0.08
Urine IgG, mg/l <3.36 <3.36 (<3.36–4.00) 0.2
Detectable urine IgG (≥3.36mg/l), N (%) 2 (12) 4 (33) 0.2
Serum uromodulin, μg/l 125 (97–142) 105 (61–144) 0.5
Urine uromodulin, mg/l 11.30 (6.38–15.50) 4.94 (2.99–14.41) 0.3
Urine uromodulin/creatinine, mg/g 11.20 (6.67–23.17) 10.07 (4.51–15.34) 0.5
#Statistically significant difference between the groups. Abbreviations: see Table 1.
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is negative correlation between HbA1c and urine uromodu-
lin, suggesting tubular impairment among patients with
worse glycemic control. Previously, Leiherer et al. [40]
demonstrated decreased concentrations of uromodulin in
urine of patients with impaired carbohydrate metabolism,
including ones with T2DM.
From practical point of view, it is important for clinical
practitioners that both glomerular (albumin, uACR) and
tubular (urine NGAL, transferrin, IgG, and uromodulin)
markers positively correlated with glycemic control, as
assessed with HbA1c measurements. Hence, good glycemic
control is important both for the glomeruli and tubules in
the early stages of diabetic nephropathy.
In a subgroup of patients, we were able to obtain longitu-
dinal data on changes in standard measures of renal function
(eGFR and uACR) over one-year observation. During the
year, patients were treated according to current recommen-
dations [12]. The concentrations of NGAL in both serum
and urine as well as urine NGAL/creatinine ratios were
correlated with decline in eGFR. We did not observe signifi-
cant correlations between eGFR changes and other studied
glomerular or tubular biomarkers. This may be caused by
the small number of patients in the longitudinally
observed subgroup, as well as by the relatively short period
of observation [14]. However, we were able to show signif-
icant associations between the concentrations of KIM-1,
NGAL, and IgG in urine and the increase in uACR in
longitudinal observation. Urine KIM-1/creatinine ratio
and NGAL/creatinine ratio were also examined by Nowak
et al. [41] who studied the association of the markers with
decline in kidney function in T2DM patients over a
follow-up period of 5–12 years. Both markers were signif-
icantly associated with renal decline in simple analysis;
however, in case of the NGAL/creatinine ratio, the associ-
ation was weak and only KIM-1 remained a significant
predictor in multiple analysis. To the contrary, we have
not observed the correlation between urine KIM-1 or
KIM-1/creatinine ratio and eGFR decline, although it
correlated with the increase in albuminuria.
Our study, in accordance to previous ones, suggests that
various pathways may be involved in early renal damage
among T2DM patients [35, 41, 42]. Although albuminuria
remains one of the most significant predictors of renal
decline [42], other markers, such as serum and urine NGAL,
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Figure 2: The correlations between percentage change in eGFR values over one-year observation and urine NGAL concentrations (a), urine
NGAL/creatinine ratios (b), serum NGAL concentrations (c) among 29 patients for whom retrospective data were available. Change in eGFR
was calculated as control eGFR − baseline eGFR /baseline eGFR ∗ 100%. Spearman R coefficients and p values are shown on the graphs.
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serum cystatin C, urine KIM-1, IgG, and transferrin, may add
to the early diagnosis of diabetic kidney disease.
The main limitations of our study are the cross-
sectional setting and relatively low number of patients. In
a subgroup of patients, we were able to obtain the longitu-
dinal data on changes in standard measures of renal
function (eGFR, uACR); however, these are retrospective
data, and the number of patients is small. In this subgroup
of patients, the studied markers were measured at the end
of the follow-up, so we were only able to evaluate the
associations between the studied markers and the changes
in renal function during the preceding year. The diagnosis
of kidney disease was not confirmed by renal biopsy, as
our patients did not have clinical indications for biopsy.
Therefore, we adopted surrogate markers of kidney dis-
ease, that is, the presence of moderately increased
albuminuria, decrease in eGFR, and increase in uACR.
Also, lack of the control group studied simultaneously
with the patients’ group limits our findings; however, we
relied on previous experience of our laboratory with most
studied markers.
In summary, the recruitment of the uniform group
of T2DM patients with eGFR> 60ml/min/1.73m2 and
uACR< 300mg/g, with exclusion of important interfering
conditions, enabled us to study the concentrations of selected
glomerular and tubular markers in early stages of DKD. In
most of our patients, the diabetes duration was below 10
years and the diabetes was well controlled. Both glomerular
(serum cystatin C, urine IgG, and transferrin) and tubular
(urine NGAL, KIM-1 and uromodulin) markers differed
significantly between patients with moderately increased
albuminuria comparing to those with normal to mildly
increased albuminuria. Serum and urine NGAL were signifi-
cantly associated with eGFR decline. Our findings indicate
that the widely available markers such as serum cystatin C,
urine IgG, transferrin, and NGAL may help in early assess-
ment of kidney disease in T2DM patients, although large
prospective studies are needed to confirm the conclusion.
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Figure 3: The associations between increase in urine albumin/creatinine ratio (uACR) over one-year observation and urine NGAL
concentrations (a), urine NGAL/creatinine ratios (b), urine KIM-1/creatinine ratios (c), and urine IgG concentrations (d) among 29
patients for whom retrospective data were available. Data are shown as median, interquartile range (box), nonoutlier range
(whiskers), and outliers (points). LOD indicates the limit of detection of urine IgG; p values in Mann–Whitney’s test are shown on
the graphs.
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